"Lymphoma, T-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
| Descriptor ID |
D016399
|
| MeSH Number(s) |
C04.557.386.480.750 C15.604.515.569.480.750 C20.683.515.761.480.750
|
| Concept/Terms |
Lymphoma, T-Cell- Lymphoma, T-Cell
- Lymphoma, T Cell
- T-Cell Lymphoma
- Lymphomas, T-Cell
- T Cell Lymphoma
- T-Cell Lymphomas
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, T-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, T-Cell".
This graph shows the total number of publications written about "Lymphoma, T-Cell" by people in this website by year, and whether "Lymphoma, T-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2002 | 2 | 2 | 4 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 1 | 3 |
| 2011 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, T-Cell" by people in Profiles.
-
Gorcey L, Lewin JM, Trufant J, Meehan SA, McLellan BN. Papular eruption associated with palifermin. J Am Acad Dermatol. 2014 Sep; 71(3):e101-2.
-
Pro B. Recent advances in the treatment of T-cell lymphoma. Clin Adv Hematol Oncol. 2011 Apr; 9(4 Suppl 8):1-16.
-
Magro CM, Porcu P, Schaefer J, Erter JW, Furman RR, Shitabata PK, Crowson AN. Cutaneous CD4+ CD56+ hematologic malignancies. J Am Acad Dermatol. 2010 Aug; 63(2):292-308.
-
Pro B, Horwitz SM, Atmar JP. Clinical roundtable monograph. Current management and treatment of T-cell lymphoma: A multidisciplinary approach. Clin Adv Hematol Oncol. 2010 Jun; 8(6):suppl 1-15.
-
Erter J, Alinari L, Darabi K, Gurcan M, Garzon R, Marcucci G, Bechtel MA, Wong H, Porcu P. New targets of therapy in T-cell lymphomas. Curr Drug Targets. 2010 Apr; 11(4):482-93.
-
Pozadzides JV, Pro B. Hepatosplenic T-cell lymphoma and TNF-a inhibitors. Expert Rev Hematol. 2009 Dec; 2(6):611-4.
-
Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10; 27(32):5425-30.
-
Leitenberger JJ, Berthelot CN, Polder KD, Pro B, McLaughlin P, Jones D, Duvic M. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol. 2008 Mar; 58(3):480-4.
-
Tone Y, Kojima Y, Furuuchi K, Brady M, Yashiro-Ohtani Y, Tykocinski ML, Tone M. OX40 gene expression is up-regulated by chromatin remodeling in its promoter region containing Sp1/Sp3, YY1, and NF-kappa B binding sites. J Immunol. 2007 Aug 1; 179(3):1760-7.
-
Pro B, McLaughlin P. Angioimmunoblastic T-cell lymphoma: still a dismal prognosis with current treatment approaches. Leuk Lymphoma. 2007 Apr; 48(4):645-6.